Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

BPC-157 Research Aging Biomarkers Comparison

Vascular Function (eNOS, NO) 40–60% increase in eNOS activity Upregulation of nitric oxide synthase; VEGF receptor activation 30–50% decline by age 60 Strong (multiple rodent models, consistent results) Most compelling anti-aging signal. Vascular health is fou

This comparison does not assign a generated winner or score.

  • Vascular Function (eNOS, NO)
  • 40–60% increase in eNOS activity
  • Upregulation of nitric oxide synthase; VEGF receptor activation
  • 30–50% decline by age 60
  • Strong (multiple rodent models, consistent results)
  • Most compelling anti-aging signal. Vascular health is foundational to tissue longevity
  • Inflammatory Cytokines (IL-6, TNF-alpha)
  • 42–50% reduction in chronic inflammation markers
  • Selective inhibition of NF-kB pathway; reduced SASP signaling
  • 200–300% increase in chronic low-grade inflammation with age
  • Moderate-strong (reproducible in inflammation models)
  • Mechanism is selective, not immunosuppressive. Critical distinction for aging applications
  • Mitochondrial ROS
  • 35% reduction without ATP impairment
  • Antioxidant pathway modulation; preserves respiratory chain function
  • ROS levels double by age 70; mitochondrial dysfunction accelerates
  • Moderate (fewer studies, but mechanistically sound)
  • Protects without over-suppressing beneficial oxidative signals. Rare among antioxidants
  • Tissue Repair Speed
  • 60% faster wound closure in diabetic models
  • Enhanced collagen synthesis; angiogenesis; MMP regulation
  • Healing time increases 40–80% in aged populations
  • Strong (wound healing is the most-studied BPC-157 endpoint)
  • Direct clinical relevance. Aging is fundamentally impaired repair capacity
  • Senescent Cell Clearance
  • 30% increase in apoptotic clearance by immune cells
  • Improved tissue microenvironment; macrophage recruitment
  • Senescent cell burden doubles every decade after age 40
  • Weak-moderate (indirect evidence only; not a direct senolytic)
  • Promising but speculative. Needs direct SASP and p16INK4a measurement in controlled studies
More references

Related material